This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

CDC Recommendations

SHINGRIX: Recommended by the CDC for the prevention of shingles1,*

The CDC states SHINGRIX is1:

Recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged ≥50 years
Recommended for the prevention of herpes zoster and related complications for immunocompetent adults who previously received zoster vaccine live (ZVL)
Preferred over ZVL for the prevention of herpes zoster and
related complications

Please see Important Considerations below.

2018 CDC Recommendations: Important Considerations Related to Alternate Dosing, Concomitant Use, Patients Previously Vaccinated With ZVL, and Persons With a Prior History of Herpes Zoster

Alternate Dosing

This article contains dosing schedule information that is inconsistent with the label. According to the Prescribing Information for SHINGRIX, 2 doses (0.5 mL each) should be administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.2

Concomitant Use

SHINGRIX was administered concomitantly with FLUARIX QUADRIVALENT (Influenza Vaccine) in an open-label clinical study of subjects 50 years and older (N=828). There was no evidence of interference in the immune response to any of the antigens contained in SHINGRIX or the coadministered vaccine.2

Patients Previously Vaccinated With ZVL

  • There are limited data on vaccination with SHINGRIX in patients previously vaccinated with ZVL compared to those not previously vaccinated with ZVL3
    • In a phase 3 study, humoral immunogenicity was non-inferior among subjects previously vaccinated at least 5 years earlier with ZVL
    • No apparent safety differences were observed between study groups within 30 days post-dose 2 of SHINGRIX 
    • Solicited local and systemic symptoms were similar between study groups
  • The levels of antibodies and immune cells that correlate with protection against shingles have not been clearly defined

Persons With a Prior History of Herpes Zoster

The pivotal clinical trials for SHINGRIX excluded patients with a prior history of herpes zoster.2

There are no head-to-head clinical trials comparing the efficacy and safety of SHINGRIX to ZVL

*ACIP recommendations adopted by CDC.

ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention.

You may also be interested in:

Only SHINGRIX delivered >90% efficacy against shingles regardless of age in those 50 years and older.2,

See how you and your staff can reconstitute SHINGRIX in four steps. Vaccinate confidently.

Talk to your patients about what to expect, including common adverse reactions.

 

  •   Data from the phase 3 ZOE-50 (≥50 years of age) trial and pooled data in individuals ≥70 years of age from the phase 3 ZOE-50 and ZOE-70 trials from subjects who received 2 doses of SHINGRIX (N=7344 and 8250, respectively) or placebo (N=7415 and 8346, respectively) and did not develop a confirmed case of herpes zoster within 1 month after the second dose. See study designs on Efficacy page for more details.2

References: 1. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR. 2018;67(3):103-108. 2. Prescribing Information for SHINGRIX. 3. Grupping K, Campora L, Douha M, et al. Immunogenicity and safety of the HZ/su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine. J Infect Dis. 2017;216(11):1343-1351.

Trademarks are property of their respective owners.